Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of EDP-938 in high-risk non-hospitalized adults with acute RSV infection
MOH_2023-02-23_012376Phase 2Not yet recruiting
- Sponsor
- Enanta Pharmaceuticals, Inc.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing EDP-938 with Placebo (2 arms). Primary endpoint: Efficacy based on daily participant-reported symptoms. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on MOH_2023-02-23_012376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-23_012376.